Stockreport

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

enGene Holdings Inc.  (ENGN) 
PDF Low rates of treatment-related adverse events (42%) and dose interruptions (1.6%)Emerging detalimogene profile supports potential first line use in patients with high-ri [Read more]